Huixin Bio
Pioneering advances in liquid biopsy diagnostics with groundbreaking biomedical technologies and an innovation-driven exosome purification system.
Pioneering advances in liquid biopsy diagnostics with groundbreaking biomedical technologies and an innovation-driven exosome purification system.
Huixin Bio is a pioneering startup in the field of liquid biopsy diagnostics, aiming to revolutionize the industry with its cutting-edge biomedical technologies and an innovation-driven exosome purification system. Founded in 2017, the company is dedicated to the research and development of world-leading biomedical technologies and products, with a particular focus on automatic exosome purification system. Its commitment to innovation and advancement has attracted the attention of investors, as evidenced by the Seed Round investment received on 19 January 2023 from South China VC. Operating within the Biopharma, Biotechnology, and Pharmaceutical industries, Huixin Bio is poised to make significant contributions to the rapidly evolving field of liquid biopsy diagnostics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 |
|
19 Jan 2023 |
No recent news or press coverage available for Huixin Bio.
We care about your data, and we'd love to use cookies make your experience better.